{"url_path":"/sec/eldn/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","accession_number":"0001193125-26-221702","cik":"0001404281","ticker":"ELDN","issuer_name":"Eledon Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221702-index.html","primary_entity_key":"0001404281","primary_entity_name":"Eledon Pharmaceuticals, Inc."},"word_count":62,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nInsider Trading Arrangements\n\nDuring the three months ended March 31, 2026, none of our officers or directors adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or constituted a “non-Rule 10b5-1 trading arrangement.”\n\n \n\n62\n\n[Table of Contents](#toc_page)"}